Kennedy is set for a confirmation hearing on January 29 as part of his nomination process, following a significant earnings report. He has reported over $11.3 million in earnings, with substantial income from law firms and various investments, promising to forfeit any interests in contingency fee cases upon confirmation. His financial portfolio includes prominent biotech and tech companies. Additionally, Kennedy has diverse income sources including books, licensing agreements, and paid endorsements, and has pledged to cease related activities if confirmed, showcasing his commitment to reducing potential conflicts of interest.
The Senate Finance Committee will hold a confirmation hearing for Kennedy’s nomination on Jan. 29, followed by a second hearing in the Senate Health, Education, Labor and Pensions Committee.
Kennedy reported earnings of over $11.3 million and pledged to divest or forfeit interests in contingency fee cases if confirmed.
His investments include CRISPR Therapeutics and Apple, and he committed to halt all related endeavors upon confirmation.
Kennedy's income also stems from books, endorsements, and speaking fees, emphasizing his diverse financial landscape.
Collection
[
|
...
]